Home › Compare › BNNNF vs ABBV
BNNNF yields 2.09% · ABBV yields 3.06%● Live data
📍 BNNNF pulled ahead of the other in Year 4
Combined, BNNNF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BNNNF + ABBV for your $10,000?
BEENOS Inc. operates in the e-commerce business in Japan and internationally. The company operates through E-Commerce and Incubation segments. The E-Commerce segment provides proxy purchasing services through Buyee; overseas forwarding through tenso.com; global shopping services through sekaimon; fashion items, interior goods, and cosmetics through FASBEE; BAKUMO, a marketing platform that allows Japanese brands to test launch their products to the Taiwanese market; and Brandear, which offers consumer-based delivery buyback services. This segment also operates monosense, which connects Japanese celebrities, public figures, and characters with product developers to create new products; Groobee, a service that allows a business to create an E-Commerce website; narabee, a SaaS type mobile order/payment service; Travel Bar, a travel media site; and Monthly Hotel, a long-stay hotel reservation services, as well as alcoholic beverage purchasing stores under the JOYLAB name. The Incubation segment is involved in the investment and consultation, and pre-monetized startup businesses. BEENOS Inc. was incorporated in 1999 and is headquartered in Tokyo, Japan.
Full BNNNF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.